121 related articles for article (PubMed ID: 9916605)
1. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker.
Pool J; Oparil S; Hedner T; Glazer R; Oddou-Stock P; Hester A
Clin Ther; 1998; 20(6):1106-14. PubMed ID: 9916605
[TBL] [Abstract][Full Text] [Related]
2. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker.
Pool JL; Glazer R; Chiang YT; Gatlin M
J Hum Hypertens; 1999 Apr; 13(4):275-81. PubMed ID: 10333347
[TBL] [Abstract][Full Text] [Related]
3. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
Black HR; Graff A; Shute D; Stoltz R; Ruff D; Levine J; Shi Y; Mallows S
J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
[TBL] [Abstract][Full Text] [Related]
5. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril.
Holwerda NJ; Fogari R; Angeli P; Porcellati C; Hereng C; Oddou-Stock P; Heath R; Bodin F
J Hypertens; 1996 Sep; 14(9):1147-51. PubMed ID: 8986917
[TBL] [Abstract][Full Text] [Related]
6. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
8. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.
Verdecchia P; Angeli F
Clin Ther; 2004 Apr; 26(4):460-72. PubMed ID: 15189744
[TBL] [Abstract][Full Text] [Related]
11. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
13. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of valsartan in patients aged > or =65 years with systolic hypertension.
Neutel JM; Bedigian MP
Clin Ther; 2000 Aug; 22(8):961-9. PubMed ID: 10972632
[TBL] [Abstract][Full Text] [Related]
15. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy.
Elmfeldt D; Olofsson B; Meredith P
Blood Press; 2002; 11(5):293-301. PubMed ID: 12458652
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension.
Oparil S; Dyke S; Harris F; Kief J; James D; Hester A; Fitzsimmons S
Clin Ther; 1996; 18(5):797-810. PubMed ID: 8930424
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies.
Ram CV
Curr Med Res Opin; 2009 Jan; 25(1):177-85. PubMed ID: 19210150
[TBL] [Abstract][Full Text] [Related]
18. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide.
Hegner G; Faust G; Freytag F; Meilenbrock S; Sullivan J; Bodin F
Eur J Clin Pharmacol; 1997; 52(3):173-7. PubMed ID: 9218922
[TBL] [Abstract][Full Text] [Related]
19. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
Elliott WJ; Calhoun DA; DeLucca PT; Gazdick LP; Kerns DE; Zeldin RK
Clin Ther; 2001 Aug; 23(8):1166-79. PubMed ID: 11558856
[TBL] [Abstract][Full Text] [Related]
20. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.
Ruilope LM; Dukat A; Böhm M; Lacourcière Y; Gong J; Lefkowitz MP
Lancet; 2010 Apr; 375(9722):1255-66. PubMed ID: 20236700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]